Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2019 Earnings Results

Crinetics Pharmaceuticals Misses on EPS, Stock Down 1.82%

Crinetics Pharmaceuticals reported a loss of $0.60 per share, but did not disclose revenue figures or future guidance. The stock fell by 1.82%, reflecting investor uncertainty due to the lack of detailed financial metrics and outlook. The company's focus remains on its clinical programs, but the absence of guidance may lead to cautious sentiment among investors.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.60	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management's commentary indicated a cautious approach as they continue to develop their pipeline. There was no specific guidance provided for future performance.

Management did not provide specific revenue figures or guidance for the upcoming quarters.

The focus remains on advancing their clinical programs.

Crinetics Pharmaceuticals Misses on EPS, Stock Down 1.82%

Key numbers

Management commentary

Crinetics Pharmaceuticals, Inc.

More earnings this week

Crinetics Pharmaceuticals Misses on EPS, Stock Down 1.82%

Key numbers

Management commentary